ardelyx
The Executive Director, Program Management will collaborate with product teams and R&D functions to translate asset strategy into integrated development plans and drive the execution of key program objectives. This role involves guiding strategic planning, managing timelines and interdependencies, identifying and mitigating risks, and facilitating timely decision-making across non-clinical, clinical, regulatory, and medical writing functions. Reporting to the Vice President of Asset Strategy, the position requires strong leadership to manage complex drug development programs from early-stage through late-stage pivotal trials.
Headquarters
Waltham, Massachusetts, United States
Company Size
201-500 employees
Founded
2007
Ardelyx is a biopharmaceutical company that discovers, develops, and commercializes first-in-class medicines for patients with unmet medical needs in gastrointestinal and cardiorenal diseases. The company markets IBSRELA (tenapanor) for irritable bowel syndrome with constipation (IBS-C) and XPHOZAH for chronic kidney disease with hyperphosphatemia, while also pursuing additional pipeline programs including chronic idiopathic constipation. Headquartered in Northern California, Ardelyx is committed to delivering novel-mechanism therapies that improve outcomes for patients with GI and kidney disorders.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for ardelyx.
74% above the average for this role
Global Development Director Scientist
AstraZeneca
Senior Manager - CMC Regulatory Affairs Biopharm Development Projects
GSK plc
Global Development Lead (GDL), Clinical Development – Lung Cancer
Revolution Medicines
Bioproduct Research and Development (BR&D) - Analytical Scientist
Eli Lilly and Company
Sr. ADME and Quantitative Pharmacology Director
Enveda
Global Development Lead (GDL), Clinical Development – GI Cancers
Revolution Medicines